DGAP-News

PAION AG: TIMOTHY E. MORRIS JOINS PAION, INC. AS A NON-EXECUTIVE DIRECTOR - Seite 2

development. Prior to AcelRx he served as a Chief Financial Officer, Senior
Vice President finance and global corporate development of VIVUS, Inc.,
from November 2004 to December 2013, overseeing finance, corporate
development, IT, human resources, legal and investor relations functions.
Prior to VIVUS, Tim Morris was Chief Financial Officer, Senior Vice
President finance, manufacturing and administration from September 2001 to
November 2004, and was a member of the Office of the President from August
2004 to November 2004 for Questcor Pharmaceuticals, Inc. Tim Morris
graduated cum laude with a bachelor of science in business with emphasis in
accounting from California State University, Chico, and is a Certified
Public Accountant.

About Remimazolam
Remimazolam is an innovative ultra-short-acting general
sedative/anesthetic. As a result of its short duration of action and good
controllability, it has the potential for an improved efficacy and safety
profile for patients, which is an important feature in procedural sedation
for the users in this indication. Remimazolam's rapid offset is a
consequence of its metabolism by tissue esterase enzymes which metabolize
the compound into an inactive metabolite. In addition, a favorable
cardiovascular stability could be shown in the indication general
anesthesia, which amongst others was reflected in a reduced need to
counteract blood pressure drops with blood pressure stabilizing drugs like
norepinephrine.

Remimazolam has potential in three indications:

- Procedural sedation (Lead indication U.S.)

- General anesthesia (Lead indication EU, Japan)

- ICU sedation (Phase II Japan)

Remimazolam is available for licensing outside China, Russia (CIS), Turkey,
the MENA Region, South Korea and Canada, where the compound is partnered
with Yichang Humanwell, R-Pharm, Hana Pharm and Pendopharm.

About PAION AG
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany, with further sites in Cambridge, UK, and New Jersey, U.S.
The company has a track record of developing hospital-based treatments for
which there is substantial unmet medical need. PAION's strategy is to
participate in the commercialization of Remimazolam and extend its business
with a focus on anesthesia/critical care products. Remimazolam is the
building block for its future marketing activities.

For more information please visit www.paion.com

PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12